Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase NA 1Phase 1 1

Status

Recruiting 3Completed 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Endocrine 1CNS 1

Conditions

Neoplasms 281Carcinoma, Non-Small-Cell Lung 251Leukemia, Myeloid, Acute 189Breast Neoplasms 151Melanoma 150Neoplasm Metastasis 148Multiple Myeloma 127Recurrence 123Colorectal Neoplasms 119Lymphoma, Non-Hodgkin 113Lymphoma 112Leukemia, Lymphocytic, Chronic, B-Cell 107Pancreatic Neoplasms 99Ovarian Neoplasms 99Precursor Cell Lymphoblastic Leukemia-Lymphoma 91Leukemia 85Prostatic Neoplasms 83Lung Neoplasms 81Lymphoma, Large B-Cell, Diffuse 77Squamous Cell Carcinoma of Head and Neck 76Glioblastoma 73Carcinoma, Renal Cell 72Myelodysplastic Syndromes 67Lymphoma, Follicular 65Brain Neoplasms 60Lymphoma, Mantle-Cell 55Sarcoma 53Stomach Neoplasms 52Head and Neck Neoplasms 52Triple Negative Breast Neoplasms 49

Interventions

spartalizumab 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Terminated × Paraganglioma × Clear all
NCT04895748 2026-03-03

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Novartis

Phase 1 Terminated
40 enrolled
CNSEndocrineGenitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡